.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Find suppliers and generic API sources

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
McKesson
Daiichi Sankyo
Dow
Cantor Fitzgerald
UBS
Colorcon
Cerilliant
QuintilesIMS
Baxter

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,939,502

« Back to Dashboard

Which drugs does patent 7,939,502 protect, and when does it expire?


Patent 7,939,502 protects BETHKIS and is included in one NDA.

This patent has thirty-three patent family members in twenty-six countries.

Summary for Patent: 7,939,502

Title:Optimised formulation of tobramycin for aerosolization
Abstract: The invention provides a tobramycin formulation for delivery by aerosolization in the form of additive-free, isotonic solution whose pH has been optimised to ensure adequate shelf-life at room temperature. Said formulation can be advantageously used for the treatment and prophylaxis of acute and chronic endobronchial infections, in particular those caused by the bacterium Pseudomonas aeruginosa associated to lung diseases such as cystic fibrosis.
Inventor(s): Malvolti; Chiara (Parma, IT), Garzia; Raffaella (Parma, IT)
Assignee: Chiesi Farmaceutici S.p.A. (Parma, IT)
Application Number:12/642,336
Patent Claim Types:
see list of patent claims
Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Chiesi Usa Inc
BETHKIS
tobramycin
SOLUTION;INHALATION201820-001Oct 12, 2012RXYesYes7,939,502► Subscribe MANAGEMENT OF CYSTIC FIBROSIS PATIENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,939,502

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
01116071Jul 02, 2001

Non-Orange Book Patents for Patent: 7,939,502

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,987,094Optimized formulation of tobramycin for aerosolization► Subscribe
8,168,598Optimised formulation of tobramycin for aerosolization► Subscribe
7,696,178Optimised formulation of tobramycin for aerosolization► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,939,502

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria267591► Subscribe
Australia2002319226► Subscribe
Bulgaria108475► Subscribe
Bulgaria66328► Subscribe
Brazil0211320► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Cerilliant
Queensland Health
QuintilesIMS
Express Scripts
Medtronic
Julphar
Fuji
Novartis
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot